Baylor University (BU)

KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab D chemotherapy vs. placebo D chemotherapy, followed by adjuvant pembrolizumab vs. placebo for earlystage TNBC (2021) Schmid P, Cortes J, Dent R, Pusztai L, Mcarthur H, Kummel S, Bergh J, et al. Conference contribution Results from CONTESSA: A phase 3 study of tesetaxel plus a reduced dose of capecitabine versus capecitabine alone in patients with HER2-, hormone receptor plus (HR plus ) metastatic breast cancer (MBC) who have previously received a taxane (2021) O'Shaughnessy J, Schwartzberg L, Piccart M, Rugo HS, Yardley DA, Cortes J, Untch M, et al. Conference contribution Matching-Adjusted Indirect Comparison of Ribociclib Plus Fulvestrant versus Palbociclib Plus Letrozole as First-Line Treatment of HR+/HER2-Advanced Breast Cancer (2021) Fasching P, Delea TE, Lu YS, De Boer R, Hurvitz SA, Moynahan A, Chandiwana D, et al. Journal article Association of Pathologic Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-Analysis (2020) Huang M, O'Shaughnessy J, Zhao J, Haiderali A, Cortes J, Ramsey SD, Briggs A, et al. Journal article, Review article KEYNOTE-522 Asian subgroup: Phase III study of neoadjuvant pembrolizumab (pembro) vs placebo (pbo) plus chemotherapy (chemo) followed by adjuvant pembro vs pbo for early triple-negative breast cancer (TNBC) (2020) Dent R, Cortes J, Pusztai L, Mcarthur HL, Kuemmel S, Bergh J, Denkert C, et al. Conference contribution Comparative effectiveness of ribociclib plus fulvestrant (RIB plus FUL) versus palbociclib plus letrozole (PAL plus LET) as first-line (1L) treatment (Tx) of HR+/HER2L advanced breast cancer (ABC) assessed by matching-adjusted indirect comparison (MAIC) (2020) Fasching P, Delea T, Lu YS, Deboer R, Hurvitz SA, Moynahan A, Chandiwana D, et al. Conference contribution KEYNOTE-522: Phase III study of pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo (pbo) plus chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC) (2019) Schmid P, Cortes J, Dent R, Pusztai L, Mcarthur HL, Kuemmel S, Bergh J, et al. Conference contribution HLA HAPLOTYPES IN 250 FAMILIES: A CORE NGS TESTING MODEL FOR THE 17TH INTERNATIONAL HLA AND IMMUNOGENETICS WORKSHOP (2019) Askar M, Madbouly A, Zhrebker L, Willis A, Kennedy S, Padros K, Rodriguez MB, et al. Conference contribution Health and Disease-Emergent States Resulting From Adaptive Social and Biological Network Interactions (2019) Sturmberg JP, Picard M, Aron DC, Bennett JM, Bircher J, Dehaven MJ, Gijzel SMW, et al. Journal article Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. (2019) House AA, Wanner C, Sarnak MJ, Pina IL, Mcintyre CW, Komenda P, Kasiske BL, et al. Journal article